HOME >> BIOLOGY >> NEWS
After 2 years, study shows Revlimid patients live longer and remain transfusion free

n MDS presented at the ASH meeting included data evaluating Revlimid in MDS not associated with a chromosome 5q abnormality. In this Phase II trial, nearly one-third of Revlimid patients achieved blood transfusion independence and remained blood transfusion free for a median duration of 41 weeks. These data results demonstrate that Revlimid can provide long-term clinical benefit in MDS patients with or without the chromosome 5q abnormality and dramatically help to improve their quality of life.

Revlimid is indicated for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Revlimid is also used as treatment in combination with dexamethasone for multiple myeloma patients who have received at least one prior therapy.


'"/>


11-Dec-2006


Page: 1 2

Related biology news :

1. After a decades-long search, scientists identify new genetic risk factors for multiple sclerosis
2. After scrutiny, preemie lung treatments turn out to be safe, effective
3. After North Korea test, what can be done to reduce the growing nuclear threat?
4. After insects attack, plants bunker sugars for later regrowth
5. After the Hurricanes
6. After the yeast is gone bacteria continue to develop flavor of sparkling wine
7. After a time-shift, mixed signals from the circadian clock
8. After flu exposure, mild exercise protects mature mice from dying
9. Allergy battle could be won in five years, says scientist
10. New study warns limited carbon market puts 20 percent of tropical forest at risk
11. Clones on task serve greater good, evolutionary study shows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... ... August 11, 2020 , ... Both Roche, based in ... into license agreements with Housey Pharma’s HMI subsidiary to gain access to its ... annual Research and Development spending in excess of US $10 billion. , Scientists ...
(Date:8/3/2020)... ... 03, 2020 , ... Accumen Inc. is helping healthcare get ... Spectrum Solutions, to provide COVID-19 saliva testing kits nationally. , “Accumen has ... than 10 years. Early in the COVID-19 crisis, we identified supply chain gaps ...
(Date:7/18/2020)... ... 2020 , ... Commercial launch readiness is a critical stage in a product ... or vaccine, the global economic downturn will only increase price pressures overall for the ... capturing full value from every product launch is critical. However, history shows that only ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... The ... centers in 16 countries, has reached its 20th anniversary of worldwide use. Introduced ... use at top universities including University of Pennsylvania, University of Michigan, University of ...
(Date:7/18/2020)... Ohio (PRWEB) , ... July 16, 2020 , ... ... data solutions to aid in the early detection and prevention of high-burden diseases, ... to enable US-based hospitals and healthcare organizations to utilize existing data in order ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson ... product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at ...
(Date:7/1/2020)... WESTMINSTER, Colo. (PRWEB) , ... ... ... providers of expert tissue data insights, today announced that the launch of ... PD-L1 results along with data about the tumor microenvironment (TME). , “Flagship’s ...
Breaking Biology Technology:
Cached News: